HRAS single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
HRAS
Disease:
Epidermal nevus, bladder urethelial carcinoma, follicular thyroid cancer, head and neck squamous cell carcinoma, kidney cancers, breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, colon adenocarcinoma, and Costello syndrome
Molecular test that utilizes NGS technology to detect mutations in HRAS gene. HRAS (Harvey rat sarcoma viral oncogene homolog) encodes the GTPase HRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. HRAS is implicated in the pathogenesis of several cancers.
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of each DNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 1.7-1.9 and 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored DNA or RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic DNA must be stored at 2–8°C for several weeks post extraction, then at –15 to –25°C for long term storage
CPT(s)
81479 or 81404
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
